Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum

Isabelle Bos*, Stephanie Vos, Frans Verhey, Philip Scheltens, Charlotte Teunissen, Sebastiaan Engelborghs, Kristel Sleegers, Giovanni Frisoni, Olivier Blin, Jill C. Richardson, Regis Bordet, Magda Tsolaki, Julius Popp, Gwendoline Peyratout, Pablo Martinez-Lage, Mikel Tainta, Alberto Lleo, Peter Johannsen, Yvonne Freund-Levi, Lutz FroelichRik Vandenberghe, Sarah Westwood, Valerija Dobricic, Frederik Barkhof, Cristina Legido-Quigley, Lars Bertram, Simon Lovestone, Johannes Streffer, Ulf Andreasson, Kaj Blennow, Henrik Zetterberg, Pieter Jelle Visser

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)644-654
Number of pages11
JournalAlzheimer's & Dementia
Volume15
Issue number5
DOIs
Publication statusPublished - May 2019

Keywords

  • Alzheimer's disease
  • Amyloid-beta
  • Neurofilament light
  • Neurogranin
  • YKL-40
  • Cognition
  • Cerebrospinal fluid
  • APOE
  • MILD COGNITIVE IMPAIRMENT
  • NEUROFILAMENT LIGHT
  • NEUROGRANIN
  • PROTEIN
  • PATHOLOGY
  • TAU
  • DEGENERATION
  • ASSOCIATION
  • GUIDELINES

Cite this

Bos, I., Vos, S., Verhey, F., Scheltens, P., Teunissen, C., Engelborghs, S., Sleegers, K., Frisoni, G., Blin, O., Richardson, J. C., Bordet, R., Tsolaki, M., Popp, J., Peyratout, G., Martinez-Lage, P., Tainta, M., Lleo, A., Johannsen, P., Freund-Levi, Y., ... Visser, P. J. (2019). Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. Alzheimer's & Dementia, 15(5), 644-654. https://doi.org/10.1016/j.jalz.2019.01.004